IL2 and neuroblastoma: A major example is the GD2 disialoganglioside, proven to be a clinically important target on neuroblastoma; this glycolipid has no peptide component and is recognized by the Dinutuximab mAb (43), and the hu14.18-IL2 immunocytokine used to cure mice of B78 melanoma in this study (4, 11), and also recognized by circulating antibody in patients immunized with a GD2-containing vaccine (44).